ライフサイエンスコーパス: cyclophosphamide

1 and produce longer lasting improvements than cyclophosphamide.

2 yte infusion followed by posttransplantation cyclophosphamide.

3 tive conditioning regimen and posttransplant cyclophosphamide.

4 th lymphoma received carmustine 300 mg/m(2), cyclophosphamide 1,500 mg/m(2) on days 2 through 5 (tota

5 avenous fludarabine (25 mg/m(2) per day) and cyclophosphamide (250 mg/m(2) per day) for the first 3 d

6 timulating factor (75 mug), with one dose of cyclophosphamide (300 mg/m(2)) 3 days before the first v

7 ents without lymphopenia received 12.5 mg/kg cyclophosphamide 4 days before kappa.CART infusion (0.2

8 200 mg/m(2)) and salvage ASCT or weekly oral cyclophosphamide (400 mg/m(2) per week for 12 weeks).

9 of adjuvant chemotherapy to CM maintenance (cyclophosphamide 50 mg/day orally continuously and metho

10 in three (8%) and four (10%) patients given cyclophosphamide 50 mg/kg and 100 mg/kg, respectively.

11 days 1-21/28 days), combined with continuous cyclophosphamide (50 mg/d) and prednisone (20 mg/d).

12 [500 mg/m(2)], epirubicin [75 mg/m(2)], and cyclophosphamide [500 mg/m(2)]; day 1 of cycles 5-8) the

13 all followed by neoadjuvant doxorubicin and cyclophosphamide (60 mg/m(2) and 600 mg/m(2) intravenous

14 eting conditioning chemotherapy (intravenous cyclophosphamide [60 mg/kg] daily for 2 days followed by

15 acil 600 mg/m(2), epirubicin 90 mg/m(2), and cyclophosphamide 600 mg/m(2)) every 3 weeks (patients in

16 ction with pentostatin (2 mg/m(2) on day 1), cyclophosphamide (600 mg/m(2) on day 1), and ofatumumab

17 ive six cycles of docetaxel (75 mg/m(2)) and cyclophosphamide (600 mg/m(2)) every 3 weeks (DC) or thr

18 three cycles of epirubicin (90 mg/m(2)) and cyclophosphamide (600 mg/m(2)) followed by three cycles

19 travenous rituximab 375 mg/m(2), intravenous cyclophosphamide 750 mg/m(2), intravenous doxorubicin 50

20 x cycles of R-CHOP (rituximab [375 mg/m(2)], cyclophosphamide [750 mg/m(2)], doxorubicin [50 mg/m(2)]

21 9831 trial compared adjuvant doxorubicin and cyclophosphamide (AC) followed by either weekly paclitax

22 phamide (TC) was superior to doxorubicin and cyclophosphamide (AC) in a trial in early breast cancer.

23 tratified by Binet stage and fludarabine and cyclophosphamide administration route (oral vs intraveno

24 five-drug induction reinforced by sequential cyclophosphamide administration, dose-dense consolidatio

25 d chimeric recipients of posttransplantation cyclophosphamide after a chimerism-ablating secondary re

26 by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide after surgery.

27 by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide after surgery.

28 ioning can be safely combined with high-dose cyclophosphamide after transplantation, and the risk of

29 pression of MYC and BCL2 in combination with cyclophosphamide also significantly slowed tumor growth

30 stage breast cancer undergoing chemotherapy (cyclophosphamide and an anthracycline) for the first tim

31 ant pleural mesothelioma received metronomic cyclophosphamide and dendritic cell-based immunotherapy.

32 We tested this hypothesis by administering cyclophosphamide and doxorubicin (Cyclo/Dox), a common t

33 e per cell division and find that cisplatin, cyclophosphamide and etoposide induce extra base substit

34 rafts were collected after mobilisation with cyclophosphamide and filgrastim.

35 eived a conditioning chemotherapy regimen of cyclophosphamide and fludarabine followed by a single in

36 Twenty of 24 patients received cyclophosphamide and fludarabine lymphodepletion and CD1

37 h marrow tumor burden, lymphodepletion using cyclophosphamide and fludarabine, higher CAR T-cell dose

38 receiving a conditioning regimen of low-dose cyclophosphamide and fludarabine.

39 poietic stem cell grafts were mobilized with cyclophosphamide and granulocyte colony-stimulating fact

40 s generated by MVA-5T4 vaccination; however, cyclophosphamide and MVA-5T4 each independently induced

41 the potential clinical effectiveness of both cyclophosphamide and mycophenolate mofetil for progressi

42 nt with different immunotherapies, including cyclophosphamide and natalizumab, did not improve her co

43 nalidomide combined with continuous low-dose cyclophosphamide and prednisone (REP) had remarkable act

44 lkylating agents (36.8%) or a combination of cyclophosphamide and rituximab (10.5%).

45 mice were given carboplatin, doxorubicin, or cyclophosphamide and were cotreated with AAV9-MIS, recom

46 similar in the group treated with busulfan, cyclophosphamide, and ATG.

47 D prophylaxis of tacrolimus, post-transplant cyclophosphamide, and CD28 blockade induces multi-lineag

48 tuximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin.

49 ng of low-dose total body irradiation (TBI), cyclophosphamide, and fludarabine (Cy/Flu/TBI200).

50 el of chemotherapy-induced gonadotoxicity by cyclophosphamide, and inhibition of mTOR complex 1 (mTOR

51 gemcitabine group; n=1576) or to epirubicin, cyclophosphamide, and paclitaxel (control group; n=1576)

52 o one of two treatment regimens: epirubicin, cyclophosphamide, and paclitaxel (four cycles of 90 mg/m

53 received neoadjuvant dose-dense doxorubicin, cyclophosphamide, and paclitaxel chemotherapy, followed

54 usion on day 1 every 3 weeks) or epirubicin, cyclophosphamide, and paclitaxel plus gemcitabine (the s

55 Immunoablation with busulfan, cyclophosphamide, and rabbit anti-thymocyte globulin was

56 e more frequently observed with fludarabine, cyclophosphamide, and rituximab (235 [84%] of 279 vs 164

57 Fludarabine, cyclophosphamide, and rituximab (FCR) achieved a high re

58 Fludarabine, cyclophosphamide, and rituximab (FCR) has represented a

59 Fludarabine, cyclophosphamide, and rituximab (FCR) is first-line trea

60 therapy with the combination of fludarabine, cyclophosphamide, and rituximab (FCR).

61 ths (95% CI not evaluable) with fludarabine, cyclophosphamide, and rituximab (HR 1.643, 90.4% CI 1.30

62 population: 282 patients in the fludarabine, cyclophosphamide, and rituximab group and 279 in the ben

63 Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab is the standard therapy

64 being treated with prednisone, fludarabine, cyclophosphamide, and rituximab presented with progressi

65 The combination of fludarabine, cyclophosphamide, and rituximab remains the standard fro

66 f infectious complications with fludarabine, cyclophosphamide, and rituximab was more pronounced in p

67 FCR (fludarabine, cyclophosphamide, and rituximab) is the current standard

68 therapy (CIT), such as combined fludarabine, cyclophosphamide, and rituximab, in the majority of pati

69 cal transplantation with the post-transplant cyclophosphamide approach but with differing patterns of

70 Use of methotrexate, ciclosporin, or cyclophosphamide as first therapy improves cytopenias in

71 study included 356 patients conditioned with cyclophosphamide associated with fractionated total body

72 We have previously shown that cyclophosphamide at 150 mg/kg resulted in excess toxicit

73 cycles of doxorubicin/vincristine/prednisone/cyclophosphamide (AV-PC).

74 er who had ceased menstruating with adjuvant cyclophosphamide-based chemotherapy, had postmenopausal

75 identical recipients received posttransplant cyclophosphamide-based graft-versus-host disease (GVHD)

76 sity conditioning regimen and posttransplant cyclophosphamide-based graft-versus-host disease (GVHD)

77 Conclusion Post-transplantation cyclophosphamide-based HAPLO transplantation results in

78 n lymphoma who received post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic

79 edge, this is the first systematic report on cyclophosphamide-based treatment of acute AMR based on m

80 The combination of cyclophosphamide/bortezomib/dexamethasone (CyBorD) showe

81 tal body irradiation (CY/TBI), busulfan plus cyclophosphamide (BU/CY), busulfan plus melphalan plus t

82 splantation platform: 247 receiving busulfan/cyclophosphamide (BuCy) conditioning (data collected ret

83 in patients treated with anthracycline plus cyclophosphamide chemotherapy (74% v 67% overall; P = .0

84 nly for adults who receive anthracycline and cyclophosphamide chemotherapy; and the addition of a neu

85 , she received three cycles of anthracycline-cyclophosphamide combination chemotherapy followed by th

86 We investigated whether cyclophosphamide combined with plasmapheresis and intrav

87 n, and trastuzumab (TCH); or doxorubicin and cyclophosphamide (conventional-dose AC) regimens.

88 report that lymphodepleting chemotherapy by cyclophosphamide (CTX) does not lead to increased availa

89 s significantly increased when the alkylator cyclophosphamide (CTX) is added to TLI/ATS conditioning.

90 cy of the anti-cancer immunomodulatory agent cyclophosphamide (CTX) relies on intestinal bacteria.

91 t fludarabine (5 days starting day -8), with cyclophosphamide (CY; days -2 and +2) for graft-versus-h

92 versus none with localized disease received cyclophosphamide (CYP) as part of the induction regimen.

93 Cyclophosphamide depleted regulatory T cells in 24 of 27

94 lidomide-dexamethasone (VTD) with bortezomib-cyclophosphamide-dexamethasone (VCD) as induction before

95 mmunotherapy combinations with rituximab and cyclophosphamide-dexamethasone, bendamustine, or bortezo

96 Prior depletion of regulatory T cells by cyclophosphamide did not increase immune responses gener

97 ministration with docetaxel, epirubicin, and cyclophosphamide did not prolong RFS or survival compare

98 dentical transplantation with posttransplant cyclophosphamide does not compromise early survival outc

99 ront-line therapy with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and predniso

100 ival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and predniso

101 ed phase III trial to compare rituximab plus cyclophosphamide, doxorubicin, vincristine, and predniso

102 ing long-term progression-free survival over cyclophosphamide, doxorubicin, vincristine, and predniso

103 CT 18-24 days after two cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and predniso

104 OG) S8736 study, where three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and predniso

105 nts subsequently treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and predniso

106 of the addition of bortezomib to rituximab, cyclophosphamide, doxorubicin, vincristine, and predniso

107 andard treatment for DLBCL of rituximab plus cyclophosphamide, doxorubicin, vincristine, and predniso

108 th DLBCL treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and predniso

109 (PET/CT) after two cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and predniso

110 similar in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and predniso

111 significantly associated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and predniso

112 dipasvir and chemotherapy (14 rituximab plus cyclophosphamide, doxorubicin, vincristine, and predniso

113 DLBCL) can be cured with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and predniso

114 omised trial of front-line chemotherapy with cyclophosphamide, doxorubicin, vincristine, and predniso

115 xorubicin, vincristine, and prednisone and 6 cyclophosphamide, doxorubicin, vincristine, and predniso

116 DLBCL cases treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and predniso

117 tients uniformly treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and predniso

118 cles of rituximab followed by four cycles of cyclophosphamide, doxorubicin, vincristine, and predniso

119 Anthracycline-containing regimens, namely cyclophosphamide, doxorubicin, vincristine, and predniso

120 unconfirmed after first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and predniso

121 luate the benefit of RT after rituximab plus cyclophosphamide, doxorubicin, vincristine, and predniso

122 cohort comprising 395 patients treated with cyclophosphamide, doxorubicin, vincristine, and predniso

123 oma (DLBCL) is rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and predniso

124 b, plus chemotherapy (six-to-eight cycles of cyclophosphamide, doxorubicin, vincristine, and predniso

125 We hypothesized that rituximab plus cyclophosphamide, doxorubicin, vincristine, and predniso

126 and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and predniso

127 leomycin, prednisone (R-ACVBP) or rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (

128 sisting of 4 cycles of R-CHOP-14 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)

129 (80% DLBCL) treated with rituximab and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)-

130 of plasma samples collected under rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone (R-C

131 mg per square meter of body-surface area) or cyclophosphamide-doxorubicin.

132 y of standard therapy, which included either cyclophosphamide/doxorubicin (AC) or cyclophosphamide/me

133 e introduction of corticosteroids and later, cyclophosphamide dramatically improved survival in patie

134 randomly assigned to receive epirubicin plus cyclophosphamide (EC; 90 and 600 mg/m(2), respectively,

135 el plus capecitabine followed by 3 cycles of cyclophosphamide, epirubicin, and capecitabine (TX+CEX).

136 cycles of docetaxel followed by 3 cycles of cyclophosphamide, epirubicin, and fluorouracil (T+CEF),

137 Cyclophosphamide equivalent dose in male survivors was s

138 of testosterone replacement (P < .001) after cyclophosphamide equivalent dose of 20 g/m(2) or greater

139 dent effects of each drug and the cumulative cyclophosphamide equivalent dose of all drugs in relatio

140 ificantly associated with reduced pregnancy; cyclophosphamide equivalent dose was associated with ris

141 lored and dose-dense adjuvant epirubicin and cyclophosphamide every 2 weeks followed by 4 cycles of t

142 with 3 cycles of fluorouracil and epirubicin-cyclophosphamide every 3 weeks followed by 3 cycles of d

143 s rituximab 500 mg/m(2) plus fludarabine and cyclophosphamide every 4 weeks for up to six cycles.

144 ent solid cancers and breast cancer, whereas cyclophosphamide exposure increases the risk of subseque

145 drugs, chemoimmunotherapy with fludarabine, cyclophosphamide (FC), and rituximab (R) remains the sta

146 erman CLL Study Group (CLL8: fludarabine and cyclophosphamide [FC] v FC plus rituximab; CLL10: FC plu

147 The preparative regimen included busulfan, cyclophosphamide, fludarabine, and rabbit anti-thymocyte

148 , 23 received EC-D (4 cycles of epirubicin + cyclophosphamide followed by 4 cycles of docetaxel at co

149 ndard chemotherapy consisting of doxorubicin-cyclophosphamide followed by weekly paclitaxel (arm A) o

150 by weekly paclitaxel (arm A) or doxorubicin-cyclophosphamide followed by weekly paclitaxel plus tras

151 acil, epirubicin [100 mg/m(2) per dose], and cyclophosphamide), followed by 3 cycles of concurrent do

152 men consisted of 4 cycles of epirubicin plus cyclophosphamide, followed by 4 courses of docetaxel.

153 oadjuvant chemotherapy with doxorubicin plus cyclophosphamide, followed by paclitaxel, and had a comp

154 se with mycophenolate mofetil for 2 years or cyclophosphamide for 1 year both resulted in significant

155 monotherapy; GFR=30-59 ml/min per 1.73 m(2): cyclophosphamide for 3 months followed by azathioprine p

156 Docetaxel and cyclophosphamide for four cycles is an acceptable non-an

157 genic drugs (e.g., oxaliplatin combined with cyclophosphamide for treatment against tumors expressing

158 ombination (5-fluorouracil, doxorubicin, and cyclophosphamide) generated an NFkappaB-IL6-dependent in

159 We hypothesized that high-dose cyclophosphamide given after G-CSF-mobilized blood cell

160 til group (95% CI 0.53-3.84) and 2.88 in the cyclophosphamide group (1.19-4.58).

161 salvage ASCT group compared with the weekly cyclophosphamide group (19 months [95% CI 16-26] vs 11 m

162 salvage ASCT group compared with the weekly cyclophosphamide group (67 months [52-not estimable] vs

163 the salvage ASCT group compared with weekly cyclophosphamide group (67 months [95% CI 55-not estimab

164 he multitarget group than in the intravenous cyclophosphamide group (83.5% vs. 63.0%; difference, 20.

165 ime to stopping treatment was shorter in the cyclophosphamide group (p=0.019).

166 Patients randomized to a cyclophosphamide group received 50 mg twice daily on tre

167 e (49 [10%] in the intravenous busulfan plus cyclophosphamide group vs 25 [7%] in the cyclophosphamid

168 ffer between the multitarget and intravenous cyclophosphamide groups (50.3% [91 of 181] vs. 52.5% [95

169 cantly in both the mycophenolate mofetil and cyclophosphamide groups.

170 plant (P = .002), and the cumulative dose of cyclophosphamide > 5 g/m(2) (P = .019), but not to the c

171 12 months of oral cyclophosphamide has been shown to alter the progression

172 , cyclosporine, plasmapheresis, thalidomide, cyclophosphamide, hemoperfusion, tumor necrosis factor i

173 se-dense concomitant regimen of epirubicin + cyclophosphamide (historically called SIM) for 6 cycles.

174 y was associated with upper tertile doses of cyclophosphamide (HR 0.60, 95% CI 0.51-0.71; p<0.0001),

175 incristine and carboplatin, alternating with cyclophosphamide, idarubicin, and vincristine, for stage

176 carboplatin and etoposide, alternating with cyclophosphamide, idarubicin, and vincristine.

177 rugs incorporating doxorubicin, vincristine, cyclophosphamide, ifosfamide, etoposide, and dactinomyci

178 men that contains docetaxel, epirubicin, and cyclophosphamide improves survival outcomes of patients

179 to determine the recommended phase 2 dose of cyclophosphamide in combination with PomDex (arm A).

180 d with autologous tumor lysate combined with cyclophosphamide in patients with mesothelioma was safe,

181 ll transplantation (ASCT) compared with oral cyclophosphamide in patients with multiple myeloma relap

182 et studying tumour bearing mice treated with cyclophosphamide in R.

183 sensitivity to a standard chemotherapy drug, cyclophosphamide, in DLBCL cell lines.

184 uction of regulatory T cells with metronomic cyclophosphamide increased the efficacy of immunotherapy

185 oxic injury, thereby preventing both IR- and cyclophosphamide-induced alopecia.

186 SAHA restored cyclophosphamide-induced bladder pathology to that of un

187 re, blocking aberrant TGF-beta signalling in cyclophosphamide-induced cystitis with TbetaR-1 inhibiti

188 eous incidence of diabetes, the incidence of cyclophosphamide-induced diabetes, or the activation of

189 Consistent with these findings, during cyclophosphamide-induced myeloablation or specific monoc

190 During myeloid replenishment after cyclophosphamide-induced myeloablation, BCAP(-/-) mice h

191 ortezomib, dexamethasone plus doxorubicin or cyclophosphamide induction followed by transplantation i

192 otrexate, and fluorouracil (CMF; 600 mg/m(2) cyclophosphamide intravenously on days 1 and 8 or 100 mg

193 Dexamethasone-rituximab-cyclophosphamide is an alternative, particularly for non

194 dentical transplantation with posttransplant cyclophosphamide is comparable with matched unrelated do

195 prednisone), and six cycles of COPP-EBV-CAD (cyclophosphamide, lomustine, vindesine, melphalan, predn

196 set of patients who received fludarabine and cyclophosphamide lymphodepletion.

197 Cyclophosphamide-mediated leukopenia reduced the size of

198 A cyclophosphamide metabolite, acrolein, caused global DNA

199 orted reactive oxygen species resulting from cyclophosphamide metabolite, acrolein, causes global met

200 owed by four 4-week cycles of either classic cyclophosphamide, methotrexate, and fluorouracil (CMF; 6

201 Immunosuppressive therapies (ie, intravenous cyclophosphamide, methotrexate, and infliximab) in these

202 either cyclophosphamide/doxorubicin (AC) or cyclophosphamide/methotrexate/fluorouracil over single-a

203 ion was 72%, 64%, and 75% for treatment with cyclophosphamide/methotrexate/fluorouracil, AC, and cape

204 month interval included rituximab infusions, cyclophosphamide/methylprednisolone infusions, prednison

205 al protocol) or with busulfan, thiotepa, and cyclophosphamide (modified protocol).

206 y (n = 19), and a combination of MVA-5T4 and cyclophosphamide (n = 18).

207 salvage ASCT (n=31 [35%]) versus oral weekly cyclophosphamide (n=44 [52%]).

208 ed to either mycophenolate mofetil (n=69) or cyclophosphamide (n=73).

209 halan and salvage ASCT (n=89) or oral weekly cyclophosphamide (n=85).

210 patients (salvage ASCT [n=7] vs oral weekly cyclophosphamide [n=5]).

211 6 patients (mycophenolate mofetil [n=63] and cyclophosphamide [n=63]) with acceptable baseline HRCT s

212 ne to docetaxel followed by doxorubicin plus cyclophosphamide neoadjuvant chemotherapy would improve

213 transplanted recipients (TBI of 850 cGy plus cyclophosphamide of 60 mg/kg per day for 2 days).

214 fludarabine of 100 mg/kg per day for 5 days, cyclophosphamide of 60 mg/kg per day for 2 days, and tot

215 n and 600 mg/m(2) intravenously administered cyclophosphamide on day 1 every 3 weeks, followed by fou

216 de was superior to six cycles of doxorubicin-cyclophosphamide once every 2 weeks and (2) that paclita

217 All patients received cyclophosphamide or rituximab.

218 g cytotoxic agents was found for exposure to cyclophosphamide (OR, 3.58; 95% CI, 0.91-14.11) followed

219 increased using MVA-5T4, metronomic low-dose cyclophosphamide, or a combination of both treatments.

220 nia induced by total body irradiation (TBI), cyclophosphamide, or Thy1 Ab-mediated T cell depletion,

221 Conditioning was performed with busulfan and cyclophosphamide (original protocol) or with busulfan, t

222 nrolled and randomly assigned to epirubicin, cyclophosphamide, paclitaxel, and gemcitabine (gemcitabi

223 y adopted in the United States: doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab (ACTH) and

224 lowed by combined bevacizumab and adriamycin/cyclophosphamide/paclitaxel chemotherapy in HER2-negativ

225 KC by gadolinium(III) chloride or of LSEC by cyclophosphamide partially restores liver replication of

226 ow-dose chemotherapy conditioning regimen of cyclophosphamide plus fludarabine.

227 lus cyclophosphamide group vs 25 [7%] in the cyclophosphamide plus TBI group) and infection (36 [7%]

228 received high-dose conditioning regimens of cyclophosphamide plus total body irradiation (CY/TBI), b

229 (arm B) or pomalidomide, dexamethasone, and cyclophosphamide (PomCyDex) 400 mg orally on days 1, 8,

230 h melphalan-prednisone-lenalidomide (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) or lenali

231 er patients on mycophenolate mofetil than on cyclophosphamide prematurely withdrew from study drug (2

232 b combined with alkylators (bendamustine and cyclophosphamide), proteasome inhibitors (bortezomib and

233 Future studies will show, whether cyclophosphamide proves to be a valuable alternative for

234 These doses of cyclophosphamide provide a framework for further regimen

235 The use of posttransplant cyclophosphamide (PT-Cy) as graft-versus-host disease (G

236 ation (Haplo-HCT) using post-transplantation cyclophosphamide (PT-Cy) is increasingly used in patient

237 Posttransplantation cyclophosphamide (PTCy) can function as single-agent GVH

238 ith biopsy-proven acute AMR with intravenous cyclophosphamide pulses (15 mg/kg adapted to age and ren

239 Treatment was completed after 6 cyclophosphamide pulses or in case of return to baseline

240 Low-dose cyclophosphamide reduced the percentage of regulatory T

241 llicles grafted onto immunodeficient mice to cyclophosphamide resembles the key features of the chemo

242 elapsed-refractory MM, where the addition of cyclophosphamide resulted in a median progression-free-s

243 Dendritic cell vaccination combined with cyclophosphamide resulted in radiographic disease contro

244 patients received second-line immunotherapy (cyclophosphamide, rituximab, or both).

245 vival (PFS) after treatment with fludarabine-cyclophosphamide-rituximab (FCR) chemoimmunotherapy.

246 erapy regimens (including anthracycline plus cyclophosphamide) should be offered a three-drug combina

247 Guidelines recommend steroid plus cyclical cyclophosphamide (St-Cp) therapy for patients with idiop

248 Immunosuppression with cyclophosphamide stabilised luciferase expression, sugge

249 es more effectively than steroids alone or a cyclophosphamide+steroids combination did, but was assoc

250 When combined with fludarabine and cyclophosphamide, subcutaneous rituximab 1600 mg achieve

251 treated with acrolein and mice treated with cyclophosphamide superior to the standard of care, mesna

252 ompared TC6 with docetaxel, doxorubicin, and cyclophosphamide (TAC6).

253 e 1500 mg twice daily) for 24 months or oral cyclophosphamide (target dose 2.0 mg/kg per day) for 12

254 Purpose Docetaxel and cyclophosphamide (TC) was superior to doxorubicin and cy

255 herapy from 2008 to 2013 using docetaxel and cyclophosphamide (TC); docetaxel, carboplatin, and trast

256 zero) occurred more often in patients given cyclophosphamide than mycophenolate mofetil.

257 pecies potentiating the anti-tumor effect of cyclophosphamide that are kept in check by the sensor NO

258 entional memory cells preferentially survive cyclophosphamide, thus suggesting that posttransplant TS

259 on, the addition of continuous low-dose oral cyclophosphamide to lenalidomide and prednisone offers a

260 and efficacy of the addition of oral weekly cyclophosphamide to standard PomDex.

261 to 4.51 (range, 0.27-10.30) after 7 days of cyclophosphamide treatment (P = 0.02).

262 Throughout decades, cyclophosphamide treatment has been proven to be effecti

263 uced the number of activated microglia after cyclophosphamide treatment in the brain.

264 model of chemobrain, we showed that chronic cyclophosphamide treatment induced significant performan

265 er and randomized to watch and wait (n = 9), cyclophosphamide treatment only (n = 9), MVA-5T4 only (n

266 Notably, in mouse models, low-dose cyclophosphamide treatment preferentially depleted CCR2(

267 nction with transcriptome analyses following cyclophosphamide treatment to reveal that Atm deficiency

268 may be preferentially eradicated by low-dose cyclophosphamide treatment.

269 g induction regimen (cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide with or wit

270 ine, and prednisone compared with rituximab, cyclophosphamide, vincristine, and prednisone (adjusted

271 ith rituximab, when used in combination with cyclophosphamide, vincristine, and prednisone (CVP) in p

272 inetics, and pharmacodynamics of GP2013 plus cyclophosphamide, vincristine, and prednisone (GP2013-CV

273 ne, and prednisone [CHOP] or eight cycles of cyclophosphamide, vincristine, and prednisone [CVP]), ev

274 FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) with R-CH

275 142 patients with FL treated with rituximab, cyclophosphamide, vincristine, and prednisone, and a cli

276 LL who received first-line hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexameth

277 s received eight cycles of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexameth

278 l response than GCB-DLBCLs in both the CHOP (cyclophosphamide, vincristine, doxorubicin, and predniso

279 or Burkitt lymphoma prompted modification of cyclophosphamide, vincristine, doxorubicin, high-dose me

280 uding twice-daily plasma exchange; pulses of cyclophosphamide, vincristine, or cyclosporine A; or sal

281 escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednis

282 BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednis

283 BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednis

284 iority of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednis

285 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednis

286 e efficacy of either rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone (R-AC

287 In addition, cyclophosphamide was found to increase sarcoma risk in a

288 Cyclophosphamide was given at 50 mg/kg per day on days 3

289 ould have greater efficacy at 24 months than cyclophosphamide was not confirmed.

290 oietic transplantation using post-transplant cyclophosphamide was originally described using bone mar

291 t a novel continuous schedule of doxorubicin-cyclophosphamide was superior to six cycles of doxorubic

292 Busulfan and cyclophosphamide was the most common conditioning regime

293 responses following induction of cystitis by cyclophosphamide were also observed in both NaV 1.7(Nav1

294 treated with four cycles of doxorubicin plus cyclophosphamide were randomly assigned to receive pacli

295 ects (including anthracyclines, taxanes, and cyclophosphamide) were defined as time-dependent covaria

296 de with alternating periods of etoposide and cyclophosphamide, whereas the other arm received placebo

297 ne and 50% for vincristine, doxorubicin, and cyclophosphamide, which shortened the treatment duration

298 enolate mofetil, 1.0 g/d, versus intravenous cyclophosphamide with a starting dose of 0.75 (adjusted

299 five [7%] mycophenolate mofetil and 11 [15%] cyclophosphamide), with most due to progressive intersti

300 whether use of oral capecitabine instead of cyclophosphamide would be non-inferior in terms of patie